{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T10:26:20Z","timestamp":1782210380192,"version":"3.54.5"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eplepsyres.2024.107382","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:21:49Z","timestamp":1715941309000},"page":"107382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database"],"prefix":"10.1016","volume":"203","author":[{"given":"Mokshal H.","family":"Porwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abrahim N.","family":"Razzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Z.","family":"Obeidat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107382_bib1","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1528-1157.1979.tb04857.x","article-title":"Remission of seizures and relapse in patients with epilepsy","volume":"20","author":"Annegers","year":"1979","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107382_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.5138","article-title":"Comments on the Evaluation of Suicidality Risk of Newer Antiseizure Medications","volume":"79","author":"Apata","year":"2022","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107382_bib3","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1056\/NEJMoa0909801","article-title":"Suicide-related events in patients treated with Antiseizure medications","volume":"363","author":"Arana","year":"2010","journal-title":"N. Engl. J. Med"},{"issue":"15","key":"10.1016\/j.eplepsyres.2024.107382_bib4","doi-asserted-by":"crossref","DOI":"10.2174\/1381612054021006","article-title":"Ion channels and epilepsy","volume":"11","author":"Armijo","year":"2005","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107382_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2020.04.016","article-title":"Suicidal ideation and suicide attempt associated with antidepressant and Antiseizure medications: Implications for treatment of chronic pain","volume":"88","author":"Bailly","year":"2021","journal-title":"Jt. Bone Spine"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/sdata.2016.26","article-title":"A curated and standardized adverse drug event resource to accelerate drug safety research","volume":"3","author":"Banda","year":"2016","journal-title":"Sci. Data"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib7","first-page":"1","article-title":"Clonazepam","author":"Basit","year":"2020","journal-title":"xPharm: Compr. Pharmacol. Ref."},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107382_bib8","first-page":"217","article-title":"Epilepsy","volume":"42","author":"Bates","year":"2015","journal-title":"Curr. Evid. -Based Paradig. Diagn. Treat. Prim. Care."},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107382_bib9","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The Epidemiology of Epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107382_bib10","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2165\/00023210-200923040-00002","article-title":"Suicidality in people taking Antiseizure medications: What is the evidence?","volume":"23","author":"Bell","year":"2009","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107382_bib11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.yebeh.2013.06.008","article-title":"New antiepileptic drug safety information is not transmitted systematically and accepted by U.S. neurologists","volume":"29","author":"Bell","year":"2013","journal-title":"Epilepsy Behav."},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107382_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157753","article-title":"OpenVigil FDA - Inspection of U.S. American Adverse Drug Events Pharmacovigilance Data and Novel Clinical Applications","volume":"11","author":"B\u00f6hm","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neuropharm.2015.01.019","article-title":"Carbamazepine and oxcarbazepine, but not eslicarbazepine, enhance excitatory synaptic transmission onto hippocampal CA1 pyramidal cells through an antagonist action at adenosine A1 receptors","volume":"93","author":"Booker","year":"2015","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107382_bib14","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107382_bib15","doi-asserted-by":"crossref","first-page":"138","DOI":"10.9740\/mhc.2018.05.138","article-title":"Antiseizure medications and suicide-related outcomes in bipolar disorder: A descriptive review of published data","volume":"8","author":"Caley","year":"2018","journal-title":"Ment. Health Clin."},{"issue":"8","key":"10.1016\/j.eplepsyres.2024.107382_bib16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1474-4422(07)70175-8","article-title":"Epilepsy and risk of suicide: a population-based case-control study","volume":"6","author":"Christensen","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2024.107382_bib17","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.yebeh.2014.09.072","article-title":"Clinical experience with perampanel: focus on psychiatric adverse effects","volume":"41","author":"Coyle","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107382_bib18","first-page":"1011","article-title":"Mining Drugs and Indications for Suicide-Related Adverse Events","volume":"2020","author":"Ding","year":"2019","journal-title":"AMIA Annu. Symp. . Proc."},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107382_bib19","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107382_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","article-title":"The anti-convulsant stiripentol acts directly on the GABA(A) receptor as a positive allosteric modulator.","volume":"56","author":"Fisher","year":"2009","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107382_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000510703","article-title":"Post-Marketing Safety Concerns with Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System","volume":"90","author":"Gastaldon","year":"2021","journal-title":"Psychother. Psychosom."},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107382_bib22","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/FPC.0b013e32835ea0b2","article-title":"Valproic acid pathway: pharmacokinetics and pharmacodynamics","volume":"23","author":"Ghodke-Puranik","year":"2013","journal-title":"Pharm. Genom."},{"issue":"12","key":"10.1016\/j.eplepsyres.2024.107382_bib23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/pds.2036","article-title":"Gabapentin and suicide attempts","volume":"19","author":"Gibbons","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107382_bib24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1528-1157.1993.tb00433.x","article-title":"Commission on Epidemiology and Prognosis, International League Against Epilepsy","volume":"34","author":"Guidelines for epidemiologic studies on epilepsy","year":"1993","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107382_bib25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1176\/ajp.129.6.738","article-title":"Aberrant response to diazepam: a new syndrome","volume":"129","author":"Hall","year":"1972","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.neuropharm.2014.09.008","article-title":"Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide","volume":"89","author":"Hebeisen","year":"2015","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.eplepsyres.2024.107382_bib27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/ana.20685","article-title":"Depression and suicide attempt as risk factors for incident unprovoked seizures","volume":"59","author":"Hesdorffer","year":"2006","journal-title":"Ann. Neurol."},{"issue":"5","key":"10.1016\/j.eplepsyres.2024.107382_bib28","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1528-1167.2009.02012.x","article-title":"The FDA alert on suicidality and Antiseizure medications: Fire or false alarm?","volume":"50","author":"Hesdorffer","year":"2009","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.eplepsyres.2024.107382_bib29","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1523\/JNEUROSCI.20-07-02470.2000","article-title":"Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus","volume":"20","author":"Hoffman","year":"2000","journal-title":"J. Neurosci."},{"key":"10.1016\/j.eplepsyres.2024.107382_bib30","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugalcdep.2016.10.036","article-title":"Effects of the benzodiazepine GABA A \u03b11-preferring antagonist 3-isopropoxy-\u03b2-carboline hydrochloride (3-ISOPBC) on alcohol seeking and self-administration in baboons","volume":"170","author":"Holtyn","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.eplepsyres.2024.107382_bib31","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.yebeh.2013.11.017","article-title":"Increased risk of suicidality on perampanel (Fycompa\u00ae)?","volume":"31","author":"Huber","year":"2014","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107382_bib32","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.yebeh.2016.10.020","article-title":"A two-year retrospective evaluation of perampanel in patients with highly drug-resistant epilepsy and cognitive impairment","volume":"66","author":"Huber","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107382_bib33","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1089\/cap.2008.1854","article-title":"Behavioral disinhibition, suicidal ideation, and self-mutilation related to clonazepam","volume":"18","author":"Kandemir","year":"2008","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.eplepsyres.2024.107382_bib34","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaneurol.2021.2480","article-title":"Suicidality Risk of Newer Antiseizure Medications: A Meta-analysis","volume":"78","author":"Klein","year":"2021","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107382_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamaneurol.2021.5141","article-title":"Comments on the Evaluation of Suicidality Risk of Newer Antiseizure Medications-Reply","volume":"79","author":"Klein","year":"2022","journal-title":"JAMA Neurol."},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107382_bib36","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0306-4522(92)90515-4","article-title":"Different action of ethosuximide on low- and high-threshold calcium currents in rat sensory neurons","volume":"51","author":"Kostyuk","year":"1992","journal-title":"Neuroscience"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106265","article-title":"Effects of seizure frequency, depression and generalized anxiety on suicidal tendency in people with epilepsy","volume":"160","author":"Liu","year":"2020","journal-title":"Epilepsy Res"},{"issue":"12","key":"10.1016\/j.eplepsyres.2024.107382_bib38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/nrneurol.2012.222","article-title":"Epilepsy: perampanel-new promise for refractory epilepsy?","volume":"8","author":"L\u00f6scher","year":"2012","journal-title":"Nat. Rev. Neurol."},{"issue":"3","key":"10.1016\/j.eplepsyres.2024.107382_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.eplepsyres.2005.03.003","article-title":"An epilepsy mutation in the beta1 subunit of the voltage-gated sodium channel results in reduced channel sensitivity to phenytoin","volume":"64","author":"Lucas","year":"2005","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib40","article-title":"U.S. Department of Health and Human Services Food and Drug Administration","author":"Mentari","year":"2003","journal-title":"Stat. Rev. Eval.: Antiseizure Medicat. Suicidality"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib41","article-title":"Associations between gabapentinoids and suicidal behaviour, unintentional overdoses, injuries, road traffic incidents, and violent crime: population based cohort study in Sweden","volume":"365","author":"Molero","year":"2019","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107382_bib42","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/epi.13267","article-title":"Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action","volume":"57","author":"Nicolas","year":"2016","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.eplepsyres.2024.107382_bib43","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1046\/j.1528-1157.2002.40001.x","article-title":"Risk factors for suicide in epilepsy: a case control study","volume":"43","author":"Nilsson","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113861","article-title":"Retrospective analysis of adverse events associated with non-stimulant ADHD medications reported to the united states food and drug administration","volume":"300","author":"Pang","year":"2021","journal-title":"Psychiatry Res"},{"issue":"14","key":"10.1016\/j.eplepsyres.2024.107382_bib45","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1001\/jama.2010.410","article-title":"Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death","volume":"303","author":"Patorno","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.eplepsyres.2024.107382_bib46","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.0003-2409.2001.02399.x","article-title":"Gabapentin: pharmacology and its use in pain management","volume":"57","author":"Rose","year":"2002","journal-title":"Anaesthesia"},{"issue":"Pt 3","key":"10.1016\/j.eplepsyres.2024.107382_bib47","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1093\/brain\/awh726","article-title":"Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study","volume":"129","author":"Sillanp\u00e4\u00e4","year":"2006","journal-title":"Brain"},{"issue":"9","key":"10.1016\/j.eplepsyres.2024.107382_bib48","doi-asserted-by":"crossref","first-page":"a022848","DOI":"10.1101\/cshperspect.a022848","article-title":"Epilepsy: A Spectrum Disorder","volume":"5","author":"Sirven","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med"},{"issue":"4","key":"10.1016\/j.eplepsyres.2024.107382_bib49","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1007\/s11064-015-1749-0","article-title":"Effects of Levetiracetam, Carbamazepine, Phenytoin, Valproate, Lamotrigine, Oxcarbazepine, Topiramate, Vinpocetine and Sertraline on Presynaptic Hippocampal Na(+) and Ca(2+) Channels Permeability.","volume":"41","author":"Sitges","year":"2016","journal-title":"Neurochem Res"},{"issue":"2","key":"10.1016\/j.eplepsyres.2024.107382_bib50","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.eplepsyres.2006.09.008","article-title":"Pharmacology and mechanism of action of pregabalin: the calcium channel alpha2-delta (alpha2-delta) subunit as a target for antiepileptic drug discovery","volume":"73","author":"Taylor","year":"2007","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2024.107382_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.107897","article-title":"Long-term safety, efficacy, and quality of life during adjunctive brivaracetam treatment in patients with uncontrolled epilepsy: An open-label follow-up trial","volume":"118","author":"Toledo","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2024.107382_bib52","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.neuint.2019.02.015","article-title":"Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues","volume":"125","author":"Walters","year":"2019","journal-title":"Neurochem Int"},{"issue":"Pt A)","key":"10.1016\/j.eplepsyres.2024.107382_bib53","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yebeh.2015.09.005","article-title":"An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam","volume":"52","author":"Yates","year":"2015","journal-title":"Epilepsy Behav."}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121124000974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T23:59:09Z","timestamp":1717631949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121124000974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":53,"alternative-id":["S0920121124000974"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107382","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An analysis of suicidal and self-injurious behavior reports with antiseizure medications in the FDA adverse event database","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2024.107382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107382"}}